PAR1 inhibition sensitizes HPV-negative HNSCC cells to ferroptosis through inhibition of the STAT3-mediated regulation of iron and lipid metabolic pathways. (PubMed, Oncogene) - May 9, 2025 - "It is worth noting that the PAR1 small molecule inhibitor Vorapaxar can further enhance the therapeutic effect of Erastin on HPV-negative HNSCC. Therefore, we propose that PAR1 participates in the progression of HPV-negative HNSCC through STAT3 and reduces the sensitivity of HPV-negative HNSCC to ferroptosis, providing a new perspective for discovering ferroptosis regulatory factors."
Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • GPX4 • SLC7A11 • STAT3
|
|
Bing Li; Chaoge Liu; Cheng Yang; Dongmei Li; Honggang Zhou; Jiao Tian; Ning Hu; Ting Xiao; Xiaoting Gu; Xiaoyu Ai
|